anti-trop-2

Sacituzumab (hRS7) is an antibody inhibitor and a humanized monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2), serving as a component of the antibody-drug conjugate sacituzumab govitecan, used for research and treatment of TROP2-high-expressing tumors such as triple-negative breast cancer.

The Anti-TROP-2 Antibody (Pr1E11) is a chimeric mouse IgG1, κ antibody targeting TROP-2 (human). Its isotype control is Mouse IgG1 kappa, Isotype Control.

Anti-TROP2 Antibody (RN927C antibody) is a human-derived monoclonal antibody (mAb) that targets TROP2. It exhibits in vitro inhibitory effects on various tumor cell lines. The Anti-TROP2 Antibody also demonstrates antitumor activity in mouse models including pancreatic PDX, ovarian PDX, lung LG0476 PDX, and triple-negative breast cancer (TNB) PDX.

Sacituzumab-MMAE Anti-TROP2 Reference Antibody is produced in CHO cells and consists of a huIgG1 heavy chain and a hukappa light chain. This compound has a predicted molecular weight (MW) of 146.06 kDa.

CL2-SN-38, a part of the antibody-drug conjugate (ADC), can conjugate with the anti-Trop-2-humanized antibody hRS7. SN-38 is an inhibitor of DNA topoisomerase I.

TL033 TFA is a component of an antibody-drug conjugate (drug-linker conjugate for ADC). It comprises a linker and a bioactive small molecule toxin. TL033 TFA can be conjugated with the antibody Sacituzumab (anti-Trop-2) to synthesize BT001021, which exhibits anticancer activity against various cancers, including breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.

TL033 forms a component of an antibody-drug conjugate (ADC) as a drug-linker conjugate. It comprises a linker and a bioactive small molecule toxin. TL033 can be conjugated with the Sacituzumab antibody (anti-Trop-2) to synthesize BT001021, which exhibits anticancer activity against various cancers, including breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.